バイオサイトジェンの創始者兼CEO。武漢大学ウィルス学・分子生物学部卒業、中国食品薬品検定研究院免疫学修士、2003年にはUniversity of Massachusetts School of Medicineの免疫学博士号取得。約30年にわたる免疫学、ゲノム編集、モデル生物疾患モデル開発、抗体医薬品研究開発の経験を持つ。2008年、米国マサチューセッツ州にてバイオサイトジェン（Biocytogen）を創設。過去十数年にわたり一介の単一モデル生物のサービス企業であったバイオサイトジェンを、ゲノム編集モデル生物開発、抗体医薬品スクリーニング、薬効薬理研究、臨床開発などを包含するプラットフォームで一体化した総合的バイオテクノロジー企業にまで変革した。バイオサイトジェンを世界的に知られる新薬発信地とするという企業理念を持つ。
Mr. Liu Bin has been our chief financial officer since May 2020.He was the financial controller at ABB Xi’an Power Capacitor Co., Ltd. from March 2003 to April 2007. He was the chief financial officer at Shiji Tianle Wholesale Asset Porfolio from June 2010 to January 2016,and also at Xinjiang Keda Julong Equity Investment Partnership. He was also the vice president of finance of Hitevision Co., Ltd. ,a company listed on the Shenzhen Stock Exchange (stock code: 002955), from December 2018 to December 2019.
Mr. Liu obtained a bachelor’s degree in applied mathematics in June 1990 from Huazhong University of Science and Technology in the PRC. He also obtained a Master of Science degree from the University of Akron in the United States in August 1995. In August 1998, he obtained a master’s degree in business administration from the Arizona State University in the United States and a master’s degree in international management from the Thunderbird School of Global Management (formerly known as the American Graduate School of International Management) in the United States.
Deputy general manager
Mr. Wang Yongliang joined our Group in July 2017. He has been our deputy general manager since July 2021 and our chief secretariat officer since December 2020. Mr. Wang worked at SinoChem Group from August 2010 to February 2014. From February 2014 to September 2015, he was a senior investment manager of China SDIC High-tech Industry Investment Corporation, formerly known as China High-tech Investment Group whose wholly-owned subsidiary HighTech Investment Development Co., Ltd. was an investor shareholder of our Company. He was also a senior investment manager, vice president and deputy investment director of Harvest Investment Management Co., Ltd. from October 2015 to July 2017. Since July 2017, he has served as an assistant to the chairman of the Board of our Company.
Mr. Wang was awarded a Bachelor of Science degree with chemistry as his major from Nankai University in the PRC in June 2007. In June 2010, he obtained a Master of Science degree with macromolecular chemistry and physics as his major from Nankai University in the PRC.
Director of Pharmacology
Dirui Li received his PhD from College of Veterinary Medicine, China Agricultural University in 2012 (majoring in veterinary biomedicine) and research focused on infection and Immunology & Recombinant Vaccines; Then he did postdoc research at China Agricultural University and Uppsala University, Sweden. In 2016, he returned to China to join Biocytogen Pharmaceuticals（Beijing）Co., Ltd, successively served as Senior Scientist of Gene Editing Department, Manager of Pharmacological Department and Senior Manager of SD Department, currently served as the head of Pharmacology Department（Beijing/Haimen）, and developed the pharmacological platform (biomarker, drug metabolism, toxicological pathology detection platform) for Pharmacology Department.
Dr. Yao received his Ph.D. degree in Pharmaceutical Engineering from Tianjin University in 2012. His research interests include protein interactions, high-throughput screening, and mechanisms of antioxidant signaling pathways. In June 2012, he joined Biocytogen. He has led or participated in the development of EGE technology for efficient gene editing, the establishment of gene editing platform for cell lines, the promotion of laboratory automation, and the work related to the development and application of SUPCETM technology. Dr. Yao has nearly ten years of experience in gene editing technology development and animal model development. He is currently the Senior Director of Future Institute.
Rong ChenMD PhD
CEO and CMO of Eucure Biopharma
Dr. Chen Zhaorong has been our deputy general manager. He has also been the CEO and CMO of Eucure. Dr. Chen was the representative of Sanofi China and the vice president of GlaxoSmithKline China. He also worked as the chief medical officer of CASI Pharmaceuticals, Inc, a biopharmaceuticals company listed on NASDAQ (stock code: CASI). From November 2016 to December 2017, he served as the chief medical officer of Phagelux (Nanjing) Biotechnology Co., Ltd. He was also the chief medical officer of Chime Biologics (Wuhan) Co., Ltd, formerly known as Xikang (Wuhan) Biopharmaceutical Co., Ltd., from January 2018 to January 2020, and Shanghai Langyu Health Technology (Group) Co., Ltd.
Dr. Chen obtained a bachelor’s degree in medicine in August 1983 and a master’s degree
in pharmacology in October 1985 from Shandong Medical University (formerly known as Shandong Medical College) in the PRC. In May 1989, he obtained a doctorate degree in philosophy from the University of Adelaide in Australia.
アルベルト・アインシュタイン医学校（Albert Einstein College of Medicine）分子細胞生物学博士課程修了、アルベルト・アインシュタイン医学校Raju Kucherlapatis研究所で分子遺伝学のポストドクター研究に従事、主として腫瘍移植マウスモデルの開発とDNA修復遺伝子の皮膚がんと直腸がんにおける機能の研究を行う。2002年-2005年、ハーバード大学医科大学院の遺伝・ゲノム学研究センター遺伝子エンジニアリング研究所執行役員を担当。2005年、ワイス製薬で主席科学顧問レベルII、分子遺伝研究所主任を担当。2009年、ファイザー製薬で主席科学顧問レベルII、主席科学顧問、抗体遺伝子エンジニアリング研究所主任、研究課題委員長を担任。2014年には北京盛諾基医薬科技有限公司にて抗体研究開発副執行責任者、2017年には生物・抗体医薬品研究開発上級副執行責任者を歴任。2018年、バイオサイトジェンに入社、上級副執行責任者兼ボストン・バイオサイトジェンの執行責任者に就任、全面的に会社の海外業務開拓の責任を負う。RenMabの技術開発と治療用候補抗体の対外授権と提携の推進や抗体の薬効薬理と遺伝子ターゲティング業務の開拓を特に担当。